PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.

PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.
Sunshine Metals (ASX:SHN) completes acquisition of Sybil Gold Project, setting stage for July-August 2025 drilling.
Downer (ASX:DOW) completes $1 billion refinancing of its sustainability linked loan facility, enhancing financial flexibility and debt maturity profile.
Immutep (ASX:IMM) reports positive Phase I results for IMP761, showing significant T cell suppression and favourable safety profile.
Stockland (ASX:SGP) announces a full-year distribution of 25.2c per Ordinary Stapled Security and introduces a Distribution Reinvestment Plan.
Smartpay Holdings Limited (ASX:SMP) finalises a Scheme Implementation Agreement with Shift4 Payments to be acquired at NZ$1.20 per share.
Metcash Limited (ASX:MTS) reports FY25 results with revenue growth and declares a final dividend of 18.0 cps fully franked.
Shift4 Payments announces the acquisition of Smartpay Holdings Limited (ASX:SMP) at NZ$1.20 per share, pending regulatory and shareholder approvals.
AML3D Limited (ASX:AL3) opens a new advanced manufacturing facility in Ohio to support US submarine programs and the AUKUS partnership.
Engenco Limited (ASX:EGN) announces an unconditional takeover offer by Elph Investments, advising shareholders to accept by June 27.